Angiotensin II in Abdominal Aortic Aneurysm: Linking GPCR Signaling, Senescence, and Vascular Remodeling

Introduction

Abdominal aortic aneurysm (AAA) remains a critical vascular pathology, typified by progressive dilation and risk of rupture within the abdominal aorta. Despite advances in imaging and surgical management, the molecular underpinnings of AAA progression and the identification of reliable early biomarkers are persistent challenges. Recently, the interplay between vasoactive peptides, such as Angiotensin II, and cellular senescence pathways has emerged as a focal point for both mechanistic and translational research. As an endogenous octapeptide hormone (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), Angiotensin II orchestrates a spectrum of effects via G protein-coupled receptor (GPCR) signaling, profoundly influencing vascular smooth muscle cell function, inflammatory responses, and extracellular matrix remodeling—all cardinal features of AAA pathogenesis.

Biochemical Properties and Experimental Utility of Angiotensin II

Angiotensin II (CAS 4474-91-3) is recognized for its potent vasopressor effects and its central role as a GPCR agonist, particularly through binding to angiotensin type 1 (AT1R) and type 2 (AT2R) receptors on vascular smooth muscle cells (VSMCs). This peptide is highly soluble in DMSO (≥234.6 mg/mL) and water (≥76.6 mg/mL), but insoluble in ethanol, allowing for versatile preparation in diverse experimental protocols. Stock solutions are typically prepared at >10 mM in sterile water and stored at -80°C for prolonged stability, supporting reproducibility in long-term studies.

Functionally, Angiotensin II mediates vasoconstriction through phospholipase C activation and subsequent inositol trisphosphate (IP3)-dependent calcium release, triggering protein kinase C-mediated intracellular signaling cascades. These pathways not only regulate vascular tone but also modulate aldosterone secretion and renal sodium reabsorption, thereby influencing systemic blood pressure and fluid homeostasis.

Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy and AAA Models

The experimental infusion of Angiotensin II is a cornerstone for AAA modeling, particularly in genetically susceptible mouse strains such as C57BL/6J (apoE–/–). Subcutaneous delivery via osmotic minipumps at 500 or 1000 ng/min/kg for 28 days reliably induces AAA, characterized by medial degradation, adventitial remodeling, and increased resistance to tissue dissection. These models facilitate the mechanistic dissection of hypertension, vascular smooth muscle cell hypertrophy, and the complex interplay of inflammatory mediators in vascular injury responses.

At the cellular level, treatment of VSMCs with 100 nM Angiotensin II for four hours robustly enhances NADH and NADPH oxidase activity, amplifying reactive oxygen species (ROS) production—a pivotal event in promoting cellular senescence and extracellular matrix remodeling. This aligns with the critical role of angiotensin receptor signaling pathways in orchestrating vascular inflammation and hypertrophy, core processes underlying AAA pathogenesis.

Linking Angiotensin II–Mediated Signaling to Cellular Senescence in AAA

Emerging evidence underscores the significance of cellular senescence in vascular aging and AAA progression. In a recent study by Zhang et al. (Journal of Cellular and Molecular Medicine, 2025), transcriptomic screening and machine learning approaches identified 19 differentially expressed senescence-related genes (DESRGs) in AAA tissue, with ETS1 and ITPR3 standing out as potential diagnostic biomarkers. Notably, ITPR3 encodes the type 3 inositol 1,4,5-trisphosphate receptor, a critical mediator of IP3-dependent calcium release—a downstream effector in Angiotensin II–driven phospholipase C signaling. The upregulation of ITPR3 and its association with senescent endothelial cells implicate Angiotensin II–induced calcium signaling as a contributor to both endothelial dysfunction and the senescence-associated secretory phenotype (SASP) in AAA.

These insights provide a mechanistic bridge linking Angiotensin II–stimulated GPCR cascades with senescence pathways. Specifically, chronic Angiotensin II exposure may accelerate cellular aging in vascular tissues, amplifying inflammatory and remodeling signals that underpin aneurysm formation and progression. Functional enrichment analysis of DESRGs further highlights the convergence of oxidative stress, calcium signaling, and transcriptional regulation (notably via ETS1) in the pathogenesis of AAA.

Implications for Cardiovascular Remodeling and Therapeutic Targeting

The multifaceted actions of Angiotensin II in AAA extend beyond its classic role as a vasopressor. Its ability to modulate vascular smooth muscle cell hypertrophy, stimulate aldosterone secretion, and promote inflammatory responses positions it as a unifying factor in the hypertension mechanism and cardiovascular remodeling investigation. The identification of senescence-related gene signatures, as demonstrated by Zhang et al., opens avenues for noninvasive AAA diagnosis and highlights potential molecular targets for intervention—particularly those downstream of angiotensin receptor signaling.

Given the centrality of phospholipase C activation and IP3-dependent calcium release in both Angiotensin II signaling and senescence biomarker regulation, targeted modulation of these pathways may offer therapeutic promise. The integration of transcriptomic biomarker discovery with established AAA models—such as the Angiotensin II infusion model—enables rigorous preclinical validation of candidate interventions aimed at disrupting the deleterious cycle of vascular injury, inflammation, and senescence-driven remodeling.

Methodological Considerations for Angiotensin II–Based AAA Research

Experimental design utilizing Angiotensin II requires precise control of dosage, delivery, and assay conditions. The peptide's high solubility in DMSO and water supports its use in both in vitro and in vivo applications, from acute signaling studies in cultured VSMCs to chronic infusion protocols in murine AAA models. Receptor binding assays typically report IC₅₀ values in the 1–10 nM range, demanding attention to concentration-dependent effects and receptor subtype selectivity. For studies focused on vascular injury inflammatory responses or cardiovascular remodeling, co-administration with inhibitors or genetic manipulation of angiotensin receptor pathways can yield mechanistic insights into downstream signaling architecture.

Furthermore, the intersection of Angiotensin II–induced signaling and senescence marker expression (such as ETS1 and ITPR3) provides a framework for integrating molecular profiling techniques—ranging from Western blotting to single-cell RNA sequencing—into AAA model systems. This approach enables the dissection of cell-type–specific responses and the identification of potential therapeutic windows for intervention.

Future Directions: Integrating Senescence Biomarkers and Angiotensin II Signaling in AAA

The confluence of Angiotensin II–mediated GPCR activation, oxidative stress, and calcium signaling with emerging senescence biomarker discovery marks a paradigm shift in AAA research. Prospective studies are warranted to elucidate the causal relationships between chronic Angiotensin II exposure, senescent cell accumulation, and aneurysm progression. The potential for noninvasive diagnosis via measurement of circulating senescence-related gene products (e.g., ETS1, ITPR3) in conjunction with established imaging modalities could facilitate earlier detection and risk stratification for AAA.

Moreover, the translation of mechanistic insights from Angiotensin II–driven models to clinical intervention strategies—such as the targeted inhibition of phospholipase C or IP3 receptor pathways—remains an area of significant therapeutic promise. As the field advances, interdisciplinary approaches integrating vascular biology, molecular genetics, and bioinformatics will be essential to fully leverage the diagnostic and therapeutic potential of these converging pathways.

Conclusion

Angiotensin II stands at the nexus of vascular physiology and pathology, serving as both a potent vasopressor and a critical mediator of GPCR signaling in AAA. Its experimental utility as a driver of vascular smooth muscle cell hypertrophy, inflammation, and remodeling underpins its widespread use in cardiovascular disease models. The recent identification of senescence-related gene signatures, particularly the involvement of the IP3-dependent calcium release pathway, elucidates new mechanistic links between Angiotensin II signaling and AAA progression. This evolving landscape holds promise for the development of biomarker-driven diagnostics and targeted interventions in AAA and related vascular disorders.

While previous articles, such as Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy..., have explored the hypertrophic effects of Angiotensin II on VSMCs, this article extends the discussion by integrating recent advances in senescence biomarker discovery and highlighting the intersection of angiotensin receptor signaling with transcriptomic changes in AAA. By situating Angiotensin II at the crossroads of GPCR-mediated signaling and cellular senescence, this piece provides novel perspectives and practical guidance for leveraging state-of-the-art molecular tools in AAA research.